Latest filing published 27 Mar 2026 for 서울제약.
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Since each purchase
- -21.1%Entry ₩2,680 · Close at T+90 ₩2,114
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
신봉환: trading record in brief
신봉환 is a declared insider of 서울제약 (chief executive), with filings sourced from DART (FSS). Over a trading history stretching from 30 November 2022 to 26 March 2026, the count stands at 2 filings.
On the market, this insider has only ever bought: 2 purchases. The totals do not cover 2 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2026 alone, the filings show 1 purchase and no sales.
The latest filing, published on 27 March 2026, reports an open-market purchase in 서울제약. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Companies and markets linked to 신봉환
Open company profiles for insider transactions, fundamentals and analyst consensus when available.